The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: What does the literature tell us?

Journal of Child and Adolescent Psychopharmacology

Volumn 15, Issue 5, 2005, Pages 787-798

  Wilens, Timothy E ^a   Monuteaux, Michael C ^a   Snyder, Lindsey E ^a   Moore, Hadley ^a   Whitley, Julia ^a   Gignac, Martin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; METHYLPHENIDATE; PEMOLINE; VENLAFAXINE;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COMORBIDITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; EVALUATION; GENERAL CONDITION IMPROVEMENT; HUMAN; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; OUTCOMES RESEARCH; RELAPSE; REVIEW; SUBSTANCE ABUSE; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIALS; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 27644550544     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2005.15.787     Document Type: Review

References (64)

1. American Academy of Pediatrics: Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108:1033-1044, 2001.
2. Berkley RA, Fischer M, Edelbrock CS, Smallish L: The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29:546-557, 1990.
3. Biederman J, Mick E, Prince J, Bostic JQ, Wilens TE, Spencer T, Wozniak J, Faraone SV: Systematic chart review of the pharmacologic treatment of comorbid attention-deficit/hyperactivity disorder in youth with bipolar disorder. J Child Adolesc Psychopharmacol 9:247-256, 1999.
4. Biederman J, Wilens T, Mick E, Faraone S, Weber W, Curtis S, Thornell A, Pfister K, Jetton J, Soriano J: Is ADHD a risk for psychoactive substance use disorder? Findings from a four-year follow-up study. J Am Acad Child Adolesc Psychiatry 36:21-29, 1997.
5. Biederman J, Wilens TE, Mick E, Milberger S, Spencer TJ, Faraone SV: Psychoactive substance use disorders in adults with attention-deficit/ hyperactivity disorder (ADHD): Effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152:1652-1658, 1995.
6. Block J, Block JH, Keyes S: Longitudinally fore-telling drug usage in adolescence: Early childhood personality and environmental precursors. Child Dev 59:336-355, 1988.
7. Brook J, Cohen P, Brook D: Longitudinal study of co-occurring psychiatric disorders and substance use. J Am Acad Child Adolesc Psychiatry 37:322-330, 1998.
8. Bukstein OG, Brent DA, Kaminer Y: Comorbidity of substance abuse and other psychiatric disorders in adolescents. Am J Psychiatry 146:1131-1141, 1989.
9. Bukstein OG, Lynch K, Molina B: ADHD in Adolescents with Alcohol and Substance Use Disorders. Chicago, IL, American Academy of Child and Adolescent Psychiatry, 1999.
10. Carroll KM, Rounsaville BJ: History and significance of childhood attention-deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 34:75-82, 1993.
11. Chassin L, Pitts SC, Prost J: Binge drinking trajectories from adolescence to emerging adulthood in a high-risk sample: Predictors and substance abuse outcomes. J Consult Clin Psychol 70:67-78, 2002.
12. Crowley T, Mikulich S, MacDonald M, Young S, Zerbe G: Substance-dependent, conduct-disordered adolescent males: Severity of diagnosis predicts 2-year outcome. Drug Alcohol Depend 49:225-237, 1998.
13. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L: Bupropion SR in adolescents with combined attention-defict/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 40:307-314, 2001.
14. DeMilio L: Psychiatric syndromes in adolescent substance abusers. Am J Psychiatry 146:1212-1214, 1989.
15. Dennis M, Titus JC, Diamond G, Donaldson J, Godley SH, Tims FM, Webb C, Kaminer Y, Babor T, Roebuck MC, Godley MD, Hamilton N, Liddle H, Scott CK: The Cannabis Youth Treatment (CYT) experiment: Rationale, study design, and analysis plans. Addiction 97(Suppl 1):16-34, 2002.
16. DerSimonian R, Laird N: Meta-analysis in clincial trials. Contr Clin Trials 7:177-188, 1986.
17. Duval S, Tweedie R: A nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. J Am Statist Assoc 95:89-98, 2000.
18. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997.
19. Gammon GD, Brown TE: Fluoxetine and methylphenidate in combination for treatment of attention-deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 3:1-10, 1993.
20. Grabowski J, Shearer J, Merrill J, Negus SS: Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29:1439-1464, 2004.
21. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S: Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41:26S-49S, 2002.
22. Hechtman L, Weiss G, Perlman T: Hyperactives as young adults: Past and current substance abuse and antisocial behavior. Am J Orthopsych 54:415-425, 1984.
23. Hovens JG, Cantwell DP, Kiriakos R: Psychiatric comorbidity in hospitalized adolescent substance abusers. J Am Acad Child Adolesc Psychiatry 33:476-483, 1994.
24. Jaffe SL: Failed attempts at intranasal abuse of Concerta J Am Acad Child Adolesc Psychiatry 41:5, 2002.
25. Kaminer Y: Clinical implications of the relationship between attention-deficit/hyperactivity disorder and psychoactive substance use disorders. Am J Addict 1:257-264, 1992.
26. King VL, Brooner RK, Kidorf MS, Stoller KB, Mirsky AF: Attention-deficit/hyperactivity disorder and treatment outcome in opioid abusers entering treatment. J Nerv Ment Dis 187:487-495, 1999.
27. Langer DH, Sweeney KP, Bartenbach DE, Davis PM, Menander KB: Evidence of lack of abuse or dependence following pemoline treatment: Results of a retrospective survey. Drug Alcohol Depend 17:213-227, 1986.
28. Levin F, Evans S, McDowell D, Brooks D, Rhum M, Kleber H: Bupropion treatment for adult ADHD and cocaine abuse. Schottsdale (AZ), CPDD June 1998 Annual Meeting, 1998a.
29. Levin FR, Evans S, Kleber HD: Prevalence of adult attention-deficit/ hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend 52:15-25, 1998b.
30. Levin FR, Evans SM, Kleber HD: Practical guidelines for the treatment of substance abusers with adult attention-deficit/hyperactivity disorder. Psychiatr Serv 50:1001-1003, 1999.
31. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E: Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis 21:1-16, 2002.
32. Levin FR, Evans SM, McDowell DM, Kleber HD: Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: A pilot study. J Clin Psychiatry 59:300-305, 1998c.
33. Mannuzza S, Gittelman-Klein R, Konig PH, Giampino TL: Hyperactive boys almost grown up: IV. Criminality and its relationship to psychiatric status. Arch Gen Psychiatry 46:1073-1079, 1989.
34. Mannuzza S, Klein RG, Bonagura N, Malloy P, Giampino TL, Addalli KA: Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 48:77-83, 1991.
35. Molina B, Pelham W: Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 112:497-507, 2003.
36. Prince J, Wilens T, Waxmonsky J, Hammerness P, Monuteaux M, Goldman S, Brown S, Van Patten S, Gonzalez-Heydrich J, Spencer T, Doyle R, Biederman J: An open study of sustained-release bupropion in adults with ADHD and substance use disorders. Philadelphia, Scientific Procedings of the American Psychiatric Association, 2002.
37. Riggs P, Leon S, Mikulich S, Pottle L: An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child & Adolesc Psychiatry 37:1271-1278, 1998.
38. Riggs PD: Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 37:331-332, 1998.
39. Riggs PD, Baker S, Mikulich SK, Young SE, Crowley TJ: Depression in substance-dependent delinquents. J Am Acad Child Adolesc Psychiatry 34:764-771, 1995.
40. Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A: A randomized, controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry 43:420-429, 2004.
41. Riggs PD, Thompson LL, Mikulich SK, Whitmore EA, Crowley TJ: An open trial of pemoline in drug-dependent delinquents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc. Psychiatry 35:1018-1024, 1996.
42. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, Edwards A, Donlin J, Pihlgren E: Double-blind, placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 10:286-294, 2002.
43. Schubiner H, Tzelepis A, Isaacson JH, Warbasse LH, Zacharek M, Musial J: The dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: Case reports and literature review. J Clin Psychiatry 56:146-150, 1995.
44. Schubiner H, Tzelepis A, Milberger S, Lockhart N, Kruger M, Kelley BJ, Schoener EP: Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 61:244-251, 2000.
45. Shekim WO, Asarnow RF, Hess E, Zaucha K, Wheeler N: A clinical and demographic profile of a sample of adults with attention-deficit/hyperactivity disorder, residual state. Compr Psychiatry 31:416-425, 1990.
46. Solhkhah R, Wilens T, Daly J, Prince J, Biederman J: Bupropion Sustained Release for Substance Abuse, ADHD, and Mood Disorders in Adolescents. New Orleans (LA), 154th Annual Meeting of the American Psychiatric Association, May 2001.
47. Spencer T, Biederman J, Wilens T: Pharmacotherapy of attention-deficit/ hyperactivity disorder: A life span perspective. In: Review of Psychiatry. Edited by Dickstein L, Riba M, Oldham J. Washington (DC), American Psychiatric Press, 1998, pp IV-87-IV-127.
48. Stata Corporation: Stata User's Guide: Release 7.0. College Station (TX), Stata Corporation, 2001.
49. Stowell R, Estroff TW: Psychiatric disorders in substance-abusing adolescent inpatients: A pilot study. J Am Acad Child Adolesc Psychiatry 31:1036-1040, 1992.
50. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F: Publication bias. In: Methods for Meta-Analysis in Medical Research. Edited by West Sussex (England), John Wiley & Sons, Ltd., 2000.
51. Upadhyaya HP, Brady KT, Sethuraman G, Sonne SC, Malcolm R: Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: A pilot study. J Clin Psychopharmacol 21:116-118, 2001.
52. Waxmonsky J, Wilens T: Substance abusing youths. In: Pediatric Psychopharmacology: Principles and Practice. Edited by Martin A, Scahill L, Charney DS, Leckman JF. New York, Oxford University Press, 2003, pp 605-616.
53. Weinberg NZ, Glantz MD: Child psychopathology risk factors for drug abuse: Overview. J Clin Child Psychol 28:290-297, 1999.
54. Weiss G, Hechtman L, Milroy T, Perlman T: Psychiatric status of hyperactives as adults: A controlled prospective 15-year followup of 63 hyperactive children. J Am Acad Child Adolesc Psychiatry 24:211-220, 1985.
55. Wilens T: Alcohol and other drug use and attention-deficit/hyperactivity disorder. Alcohol Health and Research World 22:127-130, 1998.
56. Wilens T: Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry 65:38-46, 2004a.
57. Wilens T: Subtypes of ADHD at risk for substance abuse. New York, ADHD subtypes and subgroups at risk for substance use disorders (NIDA). Symposium at the Annual Meetings of the American Psychiatric Association, May 4, 2004b.
58. Wilens T, Biederman J, Abrantes A, Spencer T: Clinical characteristics of psychiatrically referred adolescent outpatients with substance use disorders. J Am Acad Child Adolesc Psychiatry 36:941-947, 1997a.
59. Wilens T, Biederman J, Mick E: Does ADHD Affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict 7:156-163, 1998.
60. Wilens T, Faraone S, Biederman J, Gunawardene S: Does stimulant therapy of ADHD beget later substance abuse: A metanalytic review of the literature. Pediatrics 11:179-185, 2003.
61. Wilens T, Kwon A, Tanguay S, Chase R, Faraone S, Biederman J: Characteristics of adults with ADHD plus SUD: Role of psychiatric comorbidity. Am J Addict 14:319-327, 2005.
62. Wilens T, Prince J, Biederman J, Spencer T, Doyle R, Gonzalez-Heydrich J, Hammerness P, Waxmonsky J, Monuteaux M, Goldman S, Brown S, Van Patten S: An open study of sustained-release bupropion in adults with ADHD and substance use disorders. Honolulu (HI), AACAP, 2001.
63. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T: Attention-deficit/hyperactivity disorder (ADHD) is associated with early-onset substance use disorders. J Nerv Ment Dis 185:475-482, 1997b.
64. Wilens TE, Spencer T: The stimulants revisited. In: Child and Adolescent Psychiatric Clinics of North America. Edited by Stubbe C. Philadelphia, Saunders, 2000, pp 573-603.